Publication at Faculty of Medicine in Hradec Králové |
2013
Abstract
The cardiovascular risk in patients with type 2 diabetes and the possibility of influencing it are dependent primarily on the duration and staging of diabetes and on the presence of other cardiovascular risk factors. At present time, new groups of antidiabetics have been introduced.
The new antidiabetics (incretin preparations and gliflozins) heve complex positive effects (positive influence on glycaemia, body weight and sometimes on blood pressure as well) without the risk of hypoglycaemia. This means berger possibilities in terms of successfully reducing the risk of occurrence of cardiovascular diseases in type 2 diabetics, which are a global problem, both from medical and economic point of view.